Member Info for MIKODX

GloriaMarket - I wouldn't say it's the end for GDR, they dont have any large debts, only the convertible loans which only affects the value of the shares not our cashflow. With the products the company have, they wont have any problems raising capital with investors.

Yes, it showed that things have improved with the company. Fully expect this to start moving North soon, on the back of some good news which we will receive very soon.

As we announced at the beginning of 2023, FoodPrint® was installed in our first laboratory in the USA and following approvals is now live and actively commercialising FoodPrint®. Further expansion into the USA is planned, with validation and approvals currently taking place with two other laboratories in the region. Could get an update soon which I'm sure will help turn the SP around.

James says that the products we were selling abroad didn't sell because the software and training materials weren't in their local languages. I found that hard to believe, how could the company make such a big error? Did they not sell because of this, or are there other factors in play? Well, he went on to say that now that the product is available in their local languages, sales will start to come through in December. Lets see if the CEO is right or is he going to turn out like that other joker Budd.

Belgrano - Thats a grossly inaccurate statement you just made there. How can you say sales are not increasing? We virtually doubled the turnover we did last year with sales still increasing. I'm happy to see steady growth, its better than no growth at all.

The Board have stated that as well as equity or debt financing they are also actively seeking non-dilutive funding such as grants, and funding partners for the FDA approval. Gdr have a very good track record when it comes to finding other means of financing other than dilution. This is why after so many years in the business, they still have quite a small number of shares in circulation. I don't think we will be seeing any heavy dilution if any at all.

Must say, the Results was very disappointing but the Presentation gave a little hope. Was expecting to hear of increased sales generated from the further rollout in Manchester. The fact that revenue was basically zero, seems like they must be giving the damn thing away. I would have thought a ground-breaking test like the AIHL would have really taken off and be generating decent Sales by now. But by the looks of it, things have been very slow. The Chairman did say in the Presentation that he hopes to be getting good news about the AIHL test in the coming months, but they didn't sound so positive about AIHL in the Annual Report. They hardly mentioned it and when they did all they could says was we are well positioned for expansion. No actual dates or solid news of impending expansions.

The Finances look dire at the moment and they did say that the company will be looking to raise further cash end of Q1 2024. So it could be this drops some more. But on the other hand the Fundamentals are still strong and in place, we still have the AIHL test which could expand exponentially at any given moment, and we also have the stroke test which has just received big funding, and we hope to get some news on that in the coming months. The final NICE recommendation, was expected in December 2023, but that got delayed with further details not yet available. So still lots to look forward to it's just that it looks like this could fall some more before it rises. Hopefully this will happen before any dilution, as the dilution will only hinder how fast and high this rises.

I've been is shares like the old Omega Diagnostics who had the same problem when dealing with the NHS. They move very slow and there's a lot of Beaurocracy, so there's no guarantee AIHL will be rolled out as quickly as we thought. However, we still have the global market to sell to especially now we have facilities setup in USA, any news on that will see this turn around. So all in all, fundamentals are still strong and as we know sentiment alone could raise this to unbelievable heights.

Holding Firmly.

I was hoping to get in at a lower price but anyone whose been here for some time knows this particular stock is like a coiled spring. At any moment this could uncoil and take off, and when it does it flies. If I wait any longer I might have to pay a higher price. Now I can sit back and relax and see what the annual results bring. I'm sure we will be getting much better news than last year, and possibly a much better turnover now that AHCL is being rolled out.

Experienced leader in the healthcare diagnostic market with a passion for making the NHS better. Current member of the BIVDA executive board. Former Chair of the BIVDA procurement working party and member of the NHS supplier board. Always exploring ways to influence better patient outcomes, getting better value for money and supporting NHS Trusts to meet their goals. With a wide experience in procurement, supplier management, commercial management and operations - who has achieved growth, profitability, performance and engagement targets. Coming from a procurement background set in outsourcing for financial institutions, I have used my experience to help Roche and Beckman Coulter create and develop effective managed service solutions and capabilities.

Specialities : Executive Leadership, Strategic Planning, Outsourcing, Procurement, Supplier Management, Commercial Leadership, People Leader, Operational Management, Sales Management and Key Client Management.

From now to the runup of the Presentation, does the SP go up, or will it drop further down?

Will it be good news or bad?

Here's another interesting one,

https://www.voxmarkets.co.uk/articles/cambridge-nutritional-sciences-improved-operational-efficiencies-bump-up-revenue-by-44--7d002ca/

Captainswag - always has something to say and nothing positive. Why doesn't he just sell up and get lost?

Not great but certainly not the horror show some on here were trying to make out.

. Revenue increased 44% to £4.9m (H1 2022: £3.4m).

· Gross margin increased to 62.7% (H1 2022: 54.0%), largely due to production efficiencies & product mix

· Adjusted EBITDA1 £0.0m (H1 2022: restated loss £0.4m).

· Loss before tax £0.7m (H1 2022: restated loss £0.8m).

· Loss on discontinued operations £ Nil (H1 2022: restated loss of £1.2m).

· Cash balance £4.4m (H1 2022: £2.7m).

It's certainly better than last year, hopefully the trend continues into H2.

The industry partners are as follows:

Diagnostic delivery partners include Sollis; Graphnet Health; Gendius; Jiva AI; Mindfield Advertising; By Gamers for Gamers; BCN Group.

The genomics project key partners are APIS Assay Technologies; EMQN CIC; Genedrive; Epinal; Chromition; and NW Genomic Medicine Alliance Service.

The diagnostics co-investment partners are AstraZeneca; Novartis; Boehringer-Ingelheim; MSD; Roche Diagnostics; MyCardium AI; Siemens; and Dedalus.

Funding from Innovate UK has been provided through Greater Manchester’s Innovation Accelerator programme. Led by Innovate UK on behalf of UK Research and Innovation, the pilot Innovation Accelerator programme is investing £100m in 26 transformative R&D projects to accelerate the growth of three high-potential innovation clusters – Glasgow City Region, Greater Manchester and West Midlands.

I doubt the Half Year report will be great, but what makes you think it's going to be a complete horror show? The company is coming out of a major overhaul of the business, with assets and parts of the business sold off. Last year was when the overhaul started so it's expected that the SP would suffer from that. Added to that the case with the DHSC. Things should start to stabalise now that the CD4 business is gone as well as the 93 staff. Added to that all manufaturing has been transfered to Cambridge with the Alva site now obselete. This should mean lower overheads and more focus on the nutrition and health business. We'll have a better picture which direction the company is going in Thurdays presentation.

In on Thursday. Interesting to see what the SP does up until then.

Downtheswannie - I’m not your personal researcher, if you want the answer to that question, go look it up yourself.

That jolly as you call it, enabled the company's partner in Dubai to secure a 3 year deal with the Dubai Health Authority. This will allow our larger laboratory customers to process more tests more effectively and efficiently than ever before. So they didn't come back with nothing, the trip was actually a success. Need to stop spreading misinformation, not a good look.

CaptainSwag - actually, after having time over the weekend to go over the company's fundamentals I think your right, I might have jumped in a bit too early. This is the problem when your stretched for time, you rush into buying when it would have been better to wait. I've been waiting for months to avaerage down here at a decent price. 2.3 is decent but I think we will see the 1's again.

Normally when a company has warrants in circulation it hinders the SP which is one of the reasons I feel the SP has drifted. Now that the warrants have expired we may see a bit of a tick up, but overall with the company's current situation it will most likely drift some more. If this is the case and it ticks up with the warrants expiring, I will sell what I used to average down, and try to average down at a lower price. But personally I think once the mess has cleared up with the DHSC I'm sure we will bounce back up to at least 5p. I'll watch and see how this goes.

Bought some more yesterday and averaged down. IMyself like a lot on here are deeply under water, but I still feel the company is undervalued at this price hence why I bought some more. With the cancelled warrants yesterday, all we need now is some good news about the DHSC claim and I'm sure this will turn around.

Holding Firmly.